Cosmetic Surgery Market by Type (Abdominoplasty, Blepharoplasty, Breast Augmentation), Gender (Female, Male), Age Group, Treatment Area, Technology, End User - Global Forecast 2025-2032
Description
The Cosmetic Surgery Market was valued at USD 30.34 billion in 2024 and is projected to grow to USD 32.87 billion in 2025, with a CAGR of 8.48%, reaching USD 58.23 billion by 2032.
A focused orientation to the contemporary cosmetic surgery environment highlighting patient expectations, technological convergence, and regulatory pressure shaping practice evolution
The cosmetic surgery field is at a pivotal moment shaped by converging social, demographic, and technological forces. Patients increasingly approach aesthetic interventions with heightened expectations around safety, outcomes, and convenience, and providers are adapting by integrating minimally invasive technologies, enhancing perioperative pathways, and expanding cross-disciplinary collaboration. This introduction outlines the key vectors of change that practitioners, investors, and policy makers must consider as they evaluate opportunity and risk in the current environment.
Continuing technological innovation-ranging from injectable therapeutics and energy-based devices to digital diagnostics and virtual consult platforms-has broadened the spectrum of elective procedures. At the same time, the influence of social channels and shifting cultural norms has altered demand patterns across gender and age cohorts. Regulatory scrutiny, quality assurance imperatives, and an intensified focus on post-procedural outcomes are redefining how care is delivered and evaluated. Taken together, these dynamics create both complexity and opportunity for stakeholders intent on delivering differentiated services and sustainable growth.
How converging clinical innovations, demographic shifts, and consumer behavior are reshaping service delivery models, provider competitiveness, and patient expectations
The landscape of cosmetic surgery is undergoing transformative shifts driven by clinical innovation, demographic dynamics, and evolving patient behavior. Minimally invasive procedures have migrated from the periphery to mainstream practice, supported by steady improvements in injectable technologies, laser and radiofrequency platforms, and ultrasound-based approaches that reduce downtime and broaden candidacy. These technological advances are reshaping clinical pathways and enabling a continuum of care that integrates office-based therapies with surgical interventions.
Concurrently, patient demand reflects greater diversity, with an expanding male patient base and pronounced interest among younger adults who prioritize non-surgical aesthetic enhancements. Clinical settings are adapting by offering hybrid services that combine procedural efficiency with concierge-style patient experiences. At the same time, consolidation among providers and cross-specialty partnerships have strengthened regional networks, while quality and safety standards have tightened in response to public reporting and regulatory review. These shifts underscore the importance of agility in clinical operations, investment in staff training, and proactive engagement with evolving payer, accreditation, and public health expectations.
Assessing how evolving trade policies and tariff adjustments are altering procurement economics, supply chain resilience, and capital planning across cosmetic surgery settings
Recent changes to cross-border trade policies and tariff structures have created ripple effects across the supply chains that underpin cosmetic surgery, influencing device sourcing, consumables procurement, and component manufacturing. Tightened import duties and trade frictions can elevate input costs for energy-based platforms, injectable portfolios, and single-use disposables, prompting clinicians and facilities to re-evaluate procurement strategies and inventory management. In response, manufacturers and distributors are accelerating regional sourcing, negotiating longer-term supply agreements, and redesigning packaging and logistics to mitigate added cost exposure.
These adjustments translate into operational considerations for providers: capital expenditure timing may shift as practices weigh the total cost of ownership for technology acquisitions, and procurement teams may favor suppliers with diversified manufacturing footprints. Moreover, tariff-driven cost variability can influence pricing strategy and contract negotiations with larger institutional buyers. It is also important to recognize that policy changes often catalyze innovation, as suppliers invest in alternative materials and modular designs to reduce tariff vulnerability. Ultimately, a resilient supply chain posture that combines supplier diversification, inventory optimization, and clear communication across the procurement-to-clinical continuum will be essential to absorb the cumulative impact of tariff adjustments.
Precision segmentation reveals how procedural types, patient demographics, treatment areas, technologies, and care settings jointly determine strategic priorities and resource allocation
Segment-level dynamics are central to understanding where clinical and commercial investment should be directed. Based on type, practices must differentiate approaches across abdominoplasty, blepharoplasty, breast augmentation, liposuction, rhinoplasty, and rhytidectomy, since each procedure category entails distinct perioperative resource needs, recovery trajectories, and device compatibility considerations. Providers can optimize care pathways and marketing by aligning clinical protocols and staffing models to the specific requirements of each surgical type.
Based on gender, service design must reflect that female patients historically represent a larger share of elective cosmetic procedures, while male adoption is rising; tailoring communication, facility amenities, and outcome measurements to gendered preferences enhances patient engagement. Based on age group, age stratification into 18–35 years, 36–50 years, over 50 years, and under 18 years clarifies demand elasticity, preferred interventions, and consent or guardianship protocols where applicable, informing both clinical messaging and safety considerations. Based on treatment area, the distinction among body, breast, and face procedures guides device selection and staffing expertise, given variations in anatomic complexity and aesthetic goals.
Based on technology, the adoption curves for cryolipolysis, injectable technology, laser-based technology, radiofrequency-based technology, and ultrasound-based technology vary by setting and provider expertise, creating opportunities to bundle services or offer staged treatment regimens. Based on end user, performance expectations diverge across ambulatory surgical centers, cosmetic surgery clinics, dermatology clinics, hospitals, and medical spas, meaning reimbursement practices, accreditation requirements, and patient demographics will influence commercial models. Integrating these segmentation lenses yields actionable insight into where differentiated clinical programs and targeted investments will produce the most durable returns.
Comparative regional perspectives that explain how Americas, Europe Middle East and Africa, and Asia Pacific variations drive adoption patterns, regulatory approaches, and investment focus
Regional dynamics continue to shape clinical adoption patterns, investment focus, and regulatory approaches across the global landscape. In the Americas, demand centers are driven by a combination of established cosmetic surgery markets, innovation hubs, and an emphasis on service delivery efficiency; providers face intense competition on outcome transparency, patient experience, and bundled care offerings. Reimbursement heterogeneity and accreditation expectations vary by jurisdiction, and these differences influence where high-volume centers concentrate and how partnerships with device suppliers are structured.
In Europe, the Middle East and Africa, regulatory frameworks and cultural preferences create a complex mosaic of opportunity and constraint. Providers must navigate diverse approval pathways for devices and pharmaceuticals, as well as variable consumer attitudes toward aesthetic care, which affects adoption rates for newer technologies. Regional clusters with strong medical tourism inbound flows present opportunities to scale specialized centers, provided quality assurance and post-care continuity are maintained. In the Asia-Pacific region, rapid urbanization, rising disposable income among younger cohorts, and an appetite for minimally invasive services have accelerated uptake of non-surgical modalities and hybrid care models. Across all regions, cross-border talent flows, teleconsultation capabilities, and regional manufacturing footprints are increasingly decisive factors in strategic planning.
How manufacturers, providers, and nontraditional entrants are reshaping competitive dynamics through modular technology, consolidation, and outcome driven service models
Competitive dynamics in cosmetic surgery are evolving as incumbents and new entrants pursue distinct strategies around technology, channel expansion, and clinical differentiation. Device manufacturers are prioritizing modular systems that support multiple indications and streamline training requirements, while aesthetic pharmaceutical developers are extending indications and developing companion diagnostics to enhance predictability of outcomes. Distributors and service partners are refining value propositions to emphasize bundled support, training, and post-sale service, recognizing that buyer decisions increasingly hinge on total cost and clinical outcomes rather than unit price alone.
Provider groups are consolidating to capture scale advantages in procurement, staffing, and brand development, with multispecialty practices and ambulatory surgery networks developing center-of-excellence models that concentrate complex procedures and specialized teams. At the same time, non-traditional entrants, including medically oriented spas and digital-first consult platforms, are reshaping patient acquisition and funneling loosely engaged consumers toward procedural care. For investors and corporate strategists, successful players will be those who combine rigorous clinical evidence with scalable care models and robust aftercare pathways, thereby reducing variability in outcomes and strengthening patient loyalty.
Actionable strategies for leaders to strengthen clinical excellence, supply resilience, digital front ends, and collaborative aftercare to secure long term competitive advantage
To convert insight into action, industry leaders must adopt a set of pragmatic strategies that fortify clinical performance while positioning businesses for sustainable growth. First, prioritize investment in staff training and credentialing programs that ensure consistent procedural competency across settings and enhance patient safety. Second, structure procurement and vendor relationships to favor supplier diversification and flexible sourcing arrangements that reduce exposure to supply chain disruptions and tariff-related cost swings.
Third, accelerate integration of minimally invasive and energy-based offerings into bundled clinical pathways to capture demand from patients seeking reduced downtime, while ensuring these pathways are supported by robust outcome measurement and standardized consent processes. Fourth, invest in digital front-end capabilities-teleconsultation, outcome visualization, and patient education-to extend reach and improve conversion while maintaining high standards for clinical triage. Finally, pursue partnerships that scale aftercare and quality monitoring, such as shared registries or collaborative protocols, to build trust and demonstrate measurable improvement in patient outcomes over time.
A rigorous mixed methods research framework combining clinical literature review, regulatory analysis, stakeholder interviews, and supplier due diligence to support actionable conclusions
The research approach underpinning this analysis combined a structured review of primary clinical literature, regulatory filings, and publicly available policy documents with targeted industry interviews and supplier due diligence. Evidence synthesis emphasized peer-reviewed clinical outcomes, device approval timelines, and documented safety advisories, alongside interviews with clinicians, procurement specialists, and regulatory affairs experts to capture real-world implementation constraints and adoption drivers.
Data collection prioritized contemporary sources and triangulated findings to ensure reliability: regulatory documentation provided an authoritative frame for device and therapeutic availability, while clinician interviews supplied operational context and insights into procedural workflows. Supplier and distributor assessments focused on manufacturing footprints, logistics strategies, and product support capabilities. Throughout, analytical rigor was maintained by critically appraising sources, disclosing known limitations, and validating conclusions against multiple independent inputs to ensure the research supports actionable decisions.
Concluding synthesis highlighting the imperative for evidence based adoption, operational resilience, and patient centered outcomes to realize sustainable growth
In conclusion, the cosmetic surgery landscape is advancing along multiple fronts: technological innovation is expanding the array of viable interventions, demographic and behavioral shifts are reshaping demand, and policy dynamics are exerting renewed influence on supply economics. These forces interact to create a highly dynamic environment in which providers that emphasize clinical standardization, diversified sourcing, and patient-centric digital engagement will be best positioned to sustain growth and quality outcomes. While competition will intensify, the opportunity for differentiation remains strong for organizations that can align clinical excellence with operational resilience.
Looking ahead, stakeholders should maintain a disciplined focus on evidence-based adoption, continuous training, and transparent outcome reporting. By embedding these priorities into strategic planning, organizations can improve patient satisfaction, mitigate operational risk, and capture durable value as the field continues to mature.
Please Note: PDF & Excel + Online Access - 1 Year
A focused orientation to the contemporary cosmetic surgery environment highlighting patient expectations, technological convergence, and regulatory pressure shaping practice evolution
The cosmetic surgery field is at a pivotal moment shaped by converging social, demographic, and technological forces. Patients increasingly approach aesthetic interventions with heightened expectations around safety, outcomes, and convenience, and providers are adapting by integrating minimally invasive technologies, enhancing perioperative pathways, and expanding cross-disciplinary collaboration. This introduction outlines the key vectors of change that practitioners, investors, and policy makers must consider as they evaluate opportunity and risk in the current environment.
Continuing technological innovation-ranging from injectable therapeutics and energy-based devices to digital diagnostics and virtual consult platforms-has broadened the spectrum of elective procedures. At the same time, the influence of social channels and shifting cultural norms has altered demand patterns across gender and age cohorts. Regulatory scrutiny, quality assurance imperatives, and an intensified focus on post-procedural outcomes are redefining how care is delivered and evaluated. Taken together, these dynamics create both complexity and opportunity for stakeholders intent on delivering differentiated services and sustainable growth.
How converging clinical innovations, demographic shifts, and consumer behavior are reshaping service delivery models, provider competitiveness, and patient expectations
The landscape of cosmetic surgery is undergoing transformative shifts driven by clinical innovation, demographic dynamics, and evolving patient behavior. Minimally invasive procedures have migrated from the periphery to mainstream practice, supported by steady improvements in injectable technologies, laser and radiofrequency platforms, and ultrasound-based approaches that reduce downtime and broaden candidacy. These technological advances are reshaping clinical pathways and enabling a continuum of care that integrates office-based therapies with surgical interventions.
Concurrently, patient demand reflects greater diversity, with an expanding male patient base and pronounced interest among younger adults who prioritize non-surgical aesthetic enhancements. Clinical settings are adapting by offering hybrid services that combine procedural efficiency with concierge-style patient experiences. At the same time, consolidation among providers and cross-specialty partnerships have strengthened regional networks, while quality and safety standards have tightened in response to public reporting and regulatory review. These shifts underscore the importance of agility in clinical operations, investment in staff training, and proactive engagement with evolving payer, accreditation, and public health expectations.
Assessing how evolving trade policies and tariff adjustments are altering procurement economics, supply chain resilience, and capital planning across cosmetic surgery settings
Recent changes to cross-border trade policies and tariff structures have created ripple effects across the supply chains that underpin cosmetic surgery, influencing device sourcing, consumables procurement, and component manufacturing. Tightened import duties and trade frictions can elevate input costs for energy-based platforms, injectable portfolios, and single-use disposables, prompting clinicians and facilities to re-evaluate procurement strategies and inventory management. In response, manufacturers and distributors are accelerating regional sourcing, negotiating longer-term supply agreements, and redesigning packaging and logistics to mitigate added cost exposure.
These adjustments translate into operational considerations for providers: capital expenditure timing may shift as practices weigh the total cost of ownership for technology acquisitions, and procurement teams may favor suppliers with diversified manufacturing footprints. Moreover, tariff-driven cost variability can influence pricing strategy and contract negotiations with larger institutional buyers. It is also important to recognize that policy changes often catalyze innovation, as suppliers invest in alternative materials and modular designs to reduce tariff vulnerability. Ultimately, a resilient supply chain posture that combines supplier diversification, inventory optimization, and clear communication across the procurement-to-clinical continuum will be essential to absorb the cumulative impact of tariff adjustments.
Precision segmentation reveals how procedural types, patient demographics, treatment areas, technologies, and care settings jointly determine strategic priorities and resource allocation
Segment-level dynamics are central to understanding where clinical and commercial investment should be directed. Based on type, practices must differentiate approaches across abdominoplasty, blepharoplasty, breast augmentation, liposuction, rhinoplasty, and rhytidectomy, since each procedure category entails distinct perioperative resource needs, recovery trajectories, and device compatibility considerations. Providers can optimize care pathways and marketing by aligning clinical protocols and staffing models to the specific requirements of each surgical type.
Based on gender, service design must reflect that female patients historically represent a larger share of elective cosmetic procedures, while male adoption is rising; tailoring communication, facility amenities, and outcome measurements to gendered preferences enhances patient engagement. Based on age group, age stratification into 18–35 years, 36–50 years, over 50 years, and under 18 years clarifies demand elasticity, preferred interventions, and consent or guardianship protocols where applicable, informing both clinical messaging and safety considerations. Based on treatment area, the distinction among body, breast, and face procedures guides device selection and staffing expertise, given variations in anatomic complexity and aesthetic goals.
Based on technology, the adoption curves for cryolipolysis, injectable technology, laser-based technology, radiofrequency-based technology, and ultrasound-based technology vary by setting and provider expertise, creating opportunities to bundle services or offer staged treatment regimens. Based on end user, performance expectations diverge across ambulatory surgical centers, cosmetic surgery clinics, dermatology clinics, hospitals, and medical spas, meaning reimbursement practices, accreditation requirements, and patient demographics will influence commercial models. Integrating these segmentation lenses yields actionable insight into where differentiated clinical programs and targeted investments will produce the most durable returns.
Comparative regional perspectives that explain how Americas, Europe Middle East and Africa, and Asia Pacific variations drive adoption patterns, regulatory approaches, and investment focus
Regional dynamics continue to shape clinical adoption patterns, investment focus, and regulatory approaches across the global landscape. In the Americas, demand centers are driven by a combination of established cosmetic surgery markets, innovation hubs, and an emphasis on service delivery efficiency; providers face intense competition on outcome transparency, patient experience, and bundled care offerings. Reimbursement heterogeneity and accreditation expectations vary by jurisdiction, and these differences influence where high-volume centers concentrate and how partnerships with device suppliers are structured.
In Europe, the Middle East and Africa, regulatory frameworks and cultural preferences create a complex mosaic of opportunity and constraint. Providers must navigate diverse approval pathways for devices and pharmaceuticals, as well as variable consumer attitudes toward aesthetic care, which affects adoption rates for newer technologies. Regional clusters with strong medical tourism inbound flows present opportunities to scale specialized centers, provided quality assurance and post-care continuity are maintained. In the Asia-Pacific region, rapid urbanization, rising disposable income among younger cohorts, and an appetite for minimally invasive services have accelerated uptake of non-surgical modalities and hybrid care models. Across all regions, cross-border talent flows, teleconsultation capabilities, and regional manufacturing footprints are increasingly decisive factors in strategic planning.
How manufacturers, providers, and nontraditional entrants are reshaping competitive dynamics through modular technology, consolidation, and outcome driven service models
Competitive dynamics in cosmetic surgery are evolving as incumbents and new entrants pursue distinct strategies around technology, channel expansion, and clinical differentiation. Device manufacturers are prioritizing modular systems that support multiple indications and streamline training requirements, while aesthetic pharmaceutical developers are extending indications and developing companion diagnostics to enhance predictability of outcomes. Distributors and service partners are refining value propositions to emphasize bundled support, training, and post-sale service, recognizing that buyer decisions increasingly hinge on total cost and clinical outcomes rather than unit price alone.
Provider groups are consolidating to capture scale advantages in procurement, staffing, and brand development, with multispecialty practices and ambulatory surgery networks developing center-of-excellence models that concentrate complex procedures and specialized teams. At the same time, non-traditional entrants, including medically oriented spas and digital-first consult platforms, are reshaping patient acquisition and funneling loosely engaged consumers toward procedural care. For investors and corporate strategists, successful players will be those who combine rigorous clinical evidence with scalable care models and robust aftercare pathways, thereby reducing variability in outcomes and strengthening patient loyalty.
Actionable strategies for leaders to strengthen clinical excellence, supply resilience, digital front ends, and collaborative aftercare to secure long term competitive advantage
To convert insight into action, industry leaders must adopt a set of pragmatic strategies that fortify clinical performance while positioning businesses for sustainable growth. First, prioritize investment in staff training and credentialing programs that ensure consistent procedural competency across settings and enhance patient safety. Second, structure procurement and vendor relationships to favor supplier diversification and flexible sourcing arrangements that reduce exposure to supply chain disruptions and tariff-related cost swings.
Third, accelerate integration of minimally invasive and energy-based offerings into bundled clinical pathways to capture demand from patients seeking reduced downtime, while ensuring these pathways are supported by robust outcome measurement and standardized consent processes. Fourth, invest in digital front-end capabilities-teleconsultation, outcome visualization, and patient education-to extend reach and improve conversion while maintaining high standards for clinical triage. Finally, pursue partnerships that scale aftercare and quality monitoring, such as shared registries or collaborative protocols, to build trust and demonstrate measurable improvement in patient outcomes over time.
A rigorous mixed methods research framework combining clinical literature review, regulatory analysis, stakeholder interviews, and supplier due diligence to support actionable conclusions
The research approach underpinning this analysis combined a structured review of primary clinical literature, regulatory filings, and publicly available policy documents with targeted industry interviews and supplier due diligence. Evidence synthesis emphasized peer-reviewed clinical outcomes, device approval timelines, and documented safety advisories, alongside interviews with clinicians, procurement specialists, and regulatory affairs experts to capture real-world implementation constraints and adoption drivers.
Data collection prioritized contemporary sources and triangulated findings to ensure reliability: regulatory documentation provided an authoritative frame for device and therapeutic availability, while clinician interviews supplied operational context and insights into procedural workflows. Supplier and distributor assessments focused on manufacturing footprints, logistics strategies, and product support capabilities. Throughout, analytical rigor was maintained by critically appraising sources, disclosing known limitations, and validating conclusions against multiple independent inputs to ensure the research supports actionable decisions.
Concluding synthesis highlighting the imperative for evidence based adoption, operational resilience, and patient centered outcomes to realize sustainable growth
In conclusion, the cosmetic surgery landscape is advancing along multiple fronts: technological innovation is expanding the array of viable interventions, demographic and behavioral shifts are reshaping demand, and policy dynamics are exerting renewed influence on supply economics. These forces interact to create a highly dynamic environment in which providers that emphasize clinical standardization, diversified sourcing, and patient-centric digital engagement will be best positioned to sustain growth and quality outcomes. While competition will intensify, the opportunity for differentiation remains strong for organizations that can align clinical excellence with operational resilience.
Looking ahead, stakeholders should maintain a disciplined focus on evidence-based adoption, continuous training, and transparent outcome reporting. By embedding these priorities into strategic planning, organizations can improve patient satisfaction, mitigate operational risk, and capture durable value as the field continues to mature.
Please Note: PDF & Excel + Online Access - 1 Year
Table of Contents
189 Pages
- 1. Preface
- 1.1. Objectives of the Study
- 1.2. Market Segmentation & Coverage
- 1.3. Years Considered for the Study
- 1.4. Currency
- 1.5. Language
- 1.6. Stakeholders
- 2. Research Methodology
- 3. Executive Summary
- 4. Market Overview
- 5. Market Insights
- 5.1. Rising adoption of AI-driven three-dimensional surgical planning platforms for personalized procedures
- 5.2. Rapid growth in combined non-surgical injectables protocols integrating neuromodulators with biostimulatory fillers
- 5.3. Increasing demand for regenerative medicine applications with stem cell and exosome-enriched fat grafting techniques
- 5.4. Expansion of virtual consultation and telehealth follow-up services in aesthetic surgery practices
- 5.5. Surge in male-focused cosmetic procedures driven by social media influence and grooming culture shifts
- 5.6. Development of sustainable sourcing and biodegradable biopolymers for next-generation dermal fillers
- 5.7. Increasing preference for in-office minimally invasive procedures boosting growth of outpatient surgical centers
- 6. Cumulative Impact of United States Tariffs 2025
- 7. Cumulative Impact of Artificial Intelligence 2025
- 8. Cosmetic Surgery Market, by Type
- 8.1. Abdominoplasty
- 8.2. Blepharoplasty
- 8.3. Breast Augmentation
- 8.4. Liposuction
- 8.5. Rhinoplasty
- 8.6. Rhytidectomy
- 9. Cosmetic Surgery Market, by Gender
- 9.1. Female
- 9.2. Male
- 10. Cosmetic Surgery Market, by Age Group
- 10.1. 18-35 Years
- 10.2. 36-50 Years
- 10.3. Over 50 Years
- 10.4. Under 18 Years
- 11. Cosmetic Surgery Market, by Treatment Area
- 11.1. Body
- 11.2. Breast
- 11.3. Face
- 12. Cosmetic Surgery Market, by Technology
- 12.1. Cryolipolysis
- 12.2. Injectable Technology
- 12.3. Laser-based Technology
- 12.4. Radiofrequency-based Technology
- 12.5. Ultrasound-based Technology
- 13. Cosmetic Surgery Market, by End User
- 13.1. Ambulatory Surgical Centers
- 13.2. Cosmetic Surgery Clinics
- 13.3. Dermatology Clinics
- 13.4. Hospitals
- 13.5. Medical Spas
- 14. Cosmetic Surgery Market, by Region
- 14.1. Americas
- 14.1.1. North America
- 14.1.2. Latin America
- 14.2. Europe, Middle East & Africa
- 14.2.1. Europe
- 14.2.2. Middle East
- 14.2.3. Africa
- 14.3. Asia-Pacific
- 15. Cosmetic Surgery Market, by Group
- 15.1. ASEAN
- 15.2. GCC
- 15.3. European Union
- 15.4. BRICS
- 15.5. G7
- 15.6. NATO
- 16. Cosmetic Surgery Market, by Country
- 16.1. United States
- 16.2. Canada
- 16.3. Mexico
- 16.4. Brazil
- 16.5. United Kingdom
- 16.6. Germany
- 16.7. France
- 16.8. Russia
- 16.9. Italy
- 16.10. Spain
- 16.11. China
- 16.12. India
- 16.13. Japan
- 16.14. Australia
- 16.15. South Korea
- 17. Competitive Landscape
- 17.1. Market Share Analysis, 2024
- 17.2. FPNV Positioning Matrix, 2024
- 17.3. Competitive Analysis
- 17.3.1. Allergan Aesthetics
- 17.3.2. Galderma S.A.
- 17.3.3. Mentor Worldwide LLC
- 17.3.4. Sientra Inc.
- 17.3.5. Candela Corporation
- 17.3.6. Cynosure LLC
- 17.3.7. Lumenis Ltd.
- 17.3.8. Alma Lasers Ltd.
- 17.3.9. Solta Medical
- 17.3.10. Merz Aesthetics GmbH
- 17.3.11. Sinclair Pharma plc
- 17.3.12. Teoxane Laboratories
- 17.3.13. Revance Therapeutics Inc.
- 17.3.14. Prollenium Medical Technologies Inc.
- 17.3.15. Groupe Fill-Med
- 17.3.16. Croma-Pharma GmbH
- 17.3.17. Laboratoires VIVACY
- 17.3.18. Shanghai Reyoung Pharmaceutical Co. Ltd.
- 17.3.19. Hugel Inc.
- 17.3.20. Medy-Tox Inc.
- 17.3.21. LG Chem Ltd.
- 17.3.22. Daewoong Pharmaceutical Co. Ltd.
- 17.3.23. Regeneron Pharmaceuticals Inc.
- 17.3.24. Anika Therapeutics Inc.
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
